NEW YORK, Nov. 22 (GenomeWeb News) - The National Cancer Institute has awarded $9.8 million to 17 Biomarkers Developmental Laboratories within the Early Detection Research Network, the agency announced last week.
Institutions that were granted the first-year funding include the
Investigators at the BDL will examine the human genome, proteome, epitome, and metabolome to identify biomarkers that can potentially serve as early detection biomarkers and markers of progression of the disease.
"The synergized power of DNA arrays, protein arrays and bioinformatics are being used to help decipher hundreds of thousands of leads to discover unique signatures for early cancer," said Sudhir Srivastava, the chief of the cancer biomarker research group at NCI's Division of Cancer Prevention.
The NCI received 68 applications to serve as Biomarker Developmental Laboratories, out of which 17 were selected for funding. The funding is the second round of five-year funding for components of the EDRN.